A recent clinical review suggests that pairing tirzepatide with hormone therapy may lead to more effective weight loss in overweight or obese postmenopausal women. www.naijnaira.com reports.
The research, presented during the ENDO 2025 conference by the Endocrine Society in San Francisco and first shared by Knowridge, focused on how these combined treatments influence weight loss.
Tirzepatide is commonly prescribed to assist with blood sugar regulation and weight management. Hormone therapy, meanwhile, is used to manage menopause symptoms. The research found that combining both leads to greater weight reduction than tirzepatide alone.
“This is the first evidence showing the combination’s added impact on weight loss using tirzepatide and hormone therapy,” said Dr. Regina Castaneda of the Mayo Clinic.
She also referenced past outcomes involving semaglutide, suggesting this drug class could be more effective when used with hormone therapy in postmenopausal women.
Menopause often triggers changes in fat storage, energy use, and muscle mass — all of which contribute to weight gain and increased health risks.
The researchers analyzed records from 120 women over 18 months. Of those, 40 used both treatments and lost an average of 17% body weight, while 80 who used only tirzepatide lost about 14%.
Dr. Maria Hurtado Andrade noted that this combination could improve treatment plans and emphasized the need for broader access and further research.
Article updated 22 hours ago. Content is written and modified by multiple authors.
